Background: Statins are a class of cholesterol lowering drugs that affect many intracellular pathways which may have implications for chemo prevention against cancer. Epidemiological data on statins and breast cancer is conflicting. We analyzed updated data from the Women's Health Initiative (WHI) to assess the relationship between statins and breast cancer risk.
Introduction
Preclinical evidence suggests that statins, the most commonly used cholesterol lowering medications, may influence mammary cancer growth (1, 2) , but the clinical evidence is inconsistent (3) . Observational studies of statins and breast cancer risk have shown mixed results with some studies reporting an increase in risk, (4) (5) (6) (7) (8) (9) , others showing a protective effect (10) (11) (12) (13) (14) and others showing no association (15, 16) . In a previous analysis of the Women's Health Initiative (WHI) cohort, Cauley et al reported that after a mean of 6.7 years follow-up there was an 18% lower risk of invasive breast cancer seen among women who had reported use of lipophilic statins (11) . However, in further analyses limited by the small numbers of cases in medication subgroups, no specific statin was associated with a lower risk of breast cancer.
We now re-examine the relationship between statins and breast cancer risk in the WHI with approximately 4 additional years of follow-up and 3,047 additional breast cancer cases.
Materials and Methods

Study Population
The population included 154,587 postmenopausal women enrolled in the Women's Health initiative Clinical Trial (CT) (67,327) and Observational Study (OS) (87, 266) . Study implementation details have been published previously (17) (18) (19) . In brief, women aged 50-79 were enrolled in one or more of four clinical trials ( Hormone therapy (HT) which included estrogen alone and estrogen plus progesterone trials, dietary modification (DM) and calcium and vitamin D supplementation) or an observational study (OS) cohort in 40 Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited.
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Statin Exposure
Participants in the WHI were asked to bring all current prescription medications to their first screening interview. Reported medications were then matched to the Master Drug Database (First DataBank, Inc., San Bruno, CA) and duration of use for each medication was recorded. The procedures for collection of data on medication use were repeated in years 1, 3, 6 and 9 of follow-up in the CT, and in year 3 in the OS. Memory aides were not used for collection of medication use information.
Statin use was defined as any use of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitor at baseline entry into the WHI. Updated information collected at subsequent participant visits were used to measure statin use as a time dependent exposure for a secondary analysis. Statins were classified as lipophilic (lovastatin, simvastatin, fluvastatin) or hydrophilic (pravastatin and atorvastatin) (20) and by potency as low potency (fluvastatin and lovastatin), medium potency (pravastatin), and high potency (simvastatin and atorvastatin) (21) (22) (23) .
Outcome
Reported invasive breast cancer cases were initially confirmed by medical record review by trained physician adjudicators at the clinical centers. Final adjudication and coding for stage using the Surveillance Epidemiology and End Results (SEER) system was done at the Clinical Coordinating Center. Hormone receptor status and HER2 status was based on local laboratory criteria (24) . Information on potential confounding and modifying variables were collected by baseline questionnaire including baseline characteristics and known risk factors for invasive breast cancer, as well as factors associated with health care utilization and cancer screening which might impact both statin utilization and breast cancer detection. Information on baseline food habits was determined by the WHI food frequency questionnaire (25) , and interviewer administered questionnaires were used to determine hormone therapy use which was defined as any use of hormones for 3 or more months after menopause. Mammograms and breast exams were mandated by study protocol annually in the two HT trials and biennially in the DM trial. Mammograms and breast exams were not mandated in the OS and were left to the discretion of the participant's physician. Information on mammography and breast exams was collected annually in the OS. The covariates used in the analysis are listed in Table 1 .
Covariates
Statistical Methods
The characteristics of statin users at baseline were compared with those of nonusers by Chi-square tests. Annualized rates of breast cancer were calculated for statin users and nonusers at baseline. Planned selected subgroup analyses were performed by statin use duration as determined at baseline (< 1 year, 1-<3 years, >3 years), type, potency, and lipophilic status.
Women who reported using two or more statins were included in analyses that compared statin use to none, but were excluded from analyses that examined details of statin use by type, potency or lipophilic status. Separate analyses were conducted for women with ER/PR-positive and ER/PR-negative breast cancer. Hazard ratios (HRs) for breast cancer among statin users versus nonusers, and 95% confidence intervals (CIs) were computed from Cox proportional hazards analyses. Tests for the proportional hazards assumptions were conducted by a Cox model that included statin use and the interaction of statin use with follow-up time, and testing for a zero coefficient on the interaction term. Cox proportional hazards models were used to assess associations between statin use at baseline and risk of invasive breast cancer. An a priori selection of covariates was with a 10% backward selection in cox modeling was utilized to create a final multivariable adjusted model.
The base model was adjusted for age and baseline HT use and stratified by trial participation (HT, DM or OS), WHI extension study participation and age group. The final multivariable model was adjusted for age, BMI, ethnicity, smoking status, baseline HT use and duration of use, family history of breast cancer, education, hysterectomy, bilateral oophorectomy, mammogram within the last two years, age at first birth, parity, age at menarche, alcohol use, percent energy from fat, NSAID use and physical activity. Comparisons of breast cancer tumor characteristics between statin users and nonusers were based on Chi-square and Fisher Exact tests.
To evaluate the effect of change in statin use over time, final models were rerun by entering statin use as a time-dependent exposure and using updated information on statin use gathered at year 3 in the OS and years 1, 3, 6 and 9 in the CT. We censored breast cancer outcomes 3 years after the last medication update in the OS to more closely parallel statin exposure in the CT. We also performed the analysis including censored outcomes. In addition, we performed a sensitivity analysis by excluding breast cancer cases diagnosed within 2 years from baseline in order to allow for sufficient statin exposure to have an effect on risk of breast cancer.
All statistical tests were two sided with a significance level of 0.05. Analyses were conducted using Statistical Analysis Software (SAS) version 9.2.
Results
The baseline characteristics of statin users and non-users are outlined in Table 1 .
Most of the variables listed were statistically significant due to large numbers. Statin use was reported at baseline by 11,584 women (7.5%) in the WHI cohort. Statin users were more likely to be older, have higher past use of tobacco, and to have larger BMI and waist circumference. Other variables associated with statin use included: bilateral oophorectomy, hysterectomy, history of benign breast disease, mammography within the past two years, use of aspirin and NSAIDS, as well as history of diabetes, angina and myocardial infarction. Nonuse of statins was associated with current hormone therapy use, less physical activity and a diet with more than 30% of body energy from fat. There was no association between statin use and age at menarche, prior pregnancies, age at first full term pregnancy and family history of breast cancer. Table 2 shows the distribution of statin use at baseline by type, duration, potency and lipophilicity. Simvastatin was the most common statin used with 29.3% reporting it's use at baseline. The majority of statin users took lipophilic statins (69.5%) and 39.4% of users were on a statin classified as low potency, 38% high potency and 22.6% medium potency. Among users at baseline, the percentage of participants using statins for < 1 year, 1-<3 years and >=3 years was 33.25%, 33.94% and 32.8% respectively. Table 3 shows the risk of invasive breast cancer by statin use at baseline. The annualized rate of breast cancer was 0.42% among statin users and 0.42% among nonusers. In the multivariable adjusted model, there was no significant relationship between statin use and breast cancer risk (HR 0.94, 95% C.I. 0.83-1.07). There was no significant reduction in breast cancer risk for prior use of simvastatin (HR 0.87, 95% C.I 0.70-1.09) or other types of statins, utilization of 2 or more statins, lipophilicity or statin potency. Statin use for < 1 year duration was associated with a trend towards an inverse association (HR 0.78, 95% C.I. 0.63-0.98); however there was no significant trend by overall duration of use (HR 1.19, 95% CI 0.91-1.33 for 1-<3 years and HR 0.97, 95% C.I 0.79-1.19 for > 3 years p -trend 0.68). There were no significant differences in the results observed with or without censoring breast cancer outcomes 3 years after last medication update in the OS or after exclusion of breast cancer cases diagnosed within 2 years from baseline (data not shown). there was no significant reduction in risk of breast cancer for users of simvastatin (HR 0.87, 95% CI 0.71-1.07).Similarly; no significant associations were seen for other statin types, lipophilicity, or statin potency. Table 5 shows the distribution of breast cancer tumor characteristics by statin use at baseline. There were no significant differences in the distribution of tumor characteristics including stage, grade, estrogen/progesterone receptor and HER2neu status by use of statins.
In addition, we looked at the relationship between statin use at baseline and breast cancer risk stratified by other important breast cancer risk factors including hormone therapy, family history of breast cancer, waist circumference and body mass index. There were no significant interactions seen (Table 6 ).
Discussion
Our updated results from the WHI cohort showed no significant relationship between statin use and breast cancer risk, however there was a non-significant reduction in risk for simvastatin in the multivariable analyses and no significant relationship was seen for lipophilic statins as a group. These results are contrary to the previous analysis by Cauley et al (11) which showed a statistically significant reduction in risk of breast cancer associated with lipophilic statins. However our results did not show this same reduction in risk. . We also demonstrated a modestly protective effect associated with statin use of less than 1 year duration compared to multiple years which argues against biological plausibility. In our analysis, we censored breast cancer outcomes after year 6 in the OS participants in order to closely parallel exposure information available for CT participants, which was different then the methodology used in the earlier WHI analysis by Cauley et al. We also analyzed the data without censoring, and no significant differences in the results were observed (data not shown). Prior observational studies of statins and breast cancer risk have shown mixed results.
Individual studies have reported a protective effect (10-12, 14, 35) however two meta-analyses published in 2005 reported no significant association (15, 16) . The most recent meta-analyses which included 13 cohort and 11 case-control studies with 2.4 million participants and 76,759 breast cancer cases identified through January 2012 also showed no significant relationship between statins and breast cancer risk (RR 0.99, 95% CI 0.94-1.04) (3). The results from epidemiologic studies which have analyzed specific statin preparation or class have been mixed showing either no relationship (38, 39) , an increased risk of breast cancer (6, 7, 40) or a reduced breast cancer risk (10-12, 14, 35) . In one case control study, only fluvastatin was associated with a decreased risk of breast cancer (odds ratio [OR], 0.50; 95% confidence interval CI, 0.30-0.80) with no association seen overall or with lipophilic statins as a group (12) , and in another case control study, the specific type of statin was not associated with breast cancer risk, although use of statins for more than 5 years was related to a trend towards decreased risk (OR, 0.70; 95% CI, 0.40-1.0) (35) . In a record-linkage cohort study from Finland, a marginal reduction in breast cancer risk was noted for users of simvastatin (hazards ratio [HR], 0.97; 95% CI, 0.95-0.99) (14) . In the meta-analysis by Bonovas et al, 7
randomized clinical trials were included along with 9 cohort studies. Although the overall result of the meta-analysis showed no significant relationship (HR using fixed effects model of 1.04, 95% C.I. 0.81-1.33), only two randomized trials were undertaken using simvastatin. Of these, follow up. The study also lacked updated information on use of rosuvastatin and the more recently available pitavastatin as they were not widely in use during the time of the study. Our results may be biased towards the null as participants on statins could potentially not be compliant with taking the medication while non-users at baseline did not have this bias. Also, due to the observational nature of our study, the results may be biased because of unknown variables that may be associated with both breast cancer and statin use. It is unclear why a protective effect was seen associated with short duration of statin use.
In conclusion, we found no overall association between statin use and breast cancer risk however our findings raise the possibility of a marginal reduction in risk associated with simvastatin use. Genetic variation in statin metabolism has been linked to the efficacy of statins in the treatment of coronary artery disease (42) and may possibly have an impact on the effect of statins on colorectal cancer risk (43) . Future studies should assess the effect of statins on cancer risk in selected populations based on genotype. 
